Skip to main content

NEXT GENERATION TOPICAL MEDICATION TO TREAT IMMUNE RESPONSES IN ATOPIC DERMATITIS – THE MOST COMMON CAUSE OF ECZEMA

Description du projet

Next-generation topical medication for the treatment of eczema

Appel à propositions

H2020-SMEInst-2018-2020-1
Voir d’autres projets de cet appel

Régime de financement

SME-1 - SME instrument phase 1

Coordinateur

TIRMED PHARMA AB
Adresse
Spets Alviksvagen 1
16753 Bromma
Suède
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contribution de l’UE
€ 50 000